Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57,159,091
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
38,690,076
-
Shares change
-
+703,364
-
Total reported value, excl. options
-
$541,665,132
-
Value change
-
+$9,157,438
-
Number of buys
-
40
-
Number of sells
-
-24
-
Price
-
$14.00
Significant Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q2 2022
79 filings reported holding DSGN - Design Therapeutics, Inc. - Common Stock as of Q2 2022.
Design Therapeutics, Inc. - Common Stock (DSGN) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38,690,076 shares
of 57,159,091 outstanding shares and own 68% of the company stock.
Largest 10 shareholders include SR ONE CAPITAL MANAGEMENT, LP (5,626,476 shares), Cormorant Asset Management, LP (5,500,000 shares), BlackRock Inc. (3,539,936 shares), Logos Global Management LP (2,797,501 shares), EcoR1 Capital, LLC (2,634,178 shares), CITADEL ADVISORS LLC (2,545,658 shares), Avoro Capital Advisors LLC (2,222,222 shares), RA CAPITAL MANAGEMENT, L.P. (2,186,636 shares), BAKER BROS. ADVISORS LP (1,436,636 shares), and VANGUARD GROUP INC (1,280,044 shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.